AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win, offering further evidence the Big Pharma may have cracked the anti-IL-33 code.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win, offering further evidence the Big Pharma may have cracked the anti-IL-33 code.